4.7 Review

MDSC in autoimmunity

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 11, Issue 7, Pages 789-793

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2011.01.026

Keywords

MDSC; Autoimmunity; Autoimmune hepatitis; EAE; IBD; Nitric oxide

Funding

  1. NCI NIH HHS [P30 CA023108] Funding Source: Medline
  2. NIAID NIH HHS [R01 AI078195-03, R01 AI078195] Funding Source: Medline

Ask authors/readers for more resources

Myeloid derived suppressor cells (MDSC) were first described nearly two decades ago. Until recently, however, descriptions of MDSC populations were found almost exclusively in animal models of cancer or in cancer patients. Over the last few years, an increasing number of reports have been published describing populations of myeloid cells with MDSC-like properties in murine models of autoimmune disease. In contrast to the proposed deleterious role of MDSC in cancer - where these cells likely inhibit tumor immunity - in the context of autoimmunity, MDSC have the potential to suppress the autoimmune response, thereby limiting tissue injury. A logical corollary of this hypothesis is that a failure of endogenous MDSC to appropriately control autoimmune T cell responses in vivo may actually contribute to the pathogenesis of autoimmune disease. (c) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available